clinical trial · NCT06428500
QTX3046 in Patients With KRAS G12D Mutations
Advanced Solid TumorQTX3046Cetuximab
brief summary
Phase 1 study to determine the safety and tolerability of QTX3046 as a single agent or in combination with cetuximab.
started
May 30, 2024
primary completion
Jul 1, 2027
completion
Jul 1, 2027
last updated
Jul 25, 2025
official title
A Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of QTX3046 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol